- Stocks
- Healthcare
- NASDAQ: LEGN

Price (delayed)

$58.93

Market cap

$10.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$9.9B

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated

The gross profit has grown by 27% from the previous quarter

The EPS has increased by 21% year-on-year and by 12% since the previous quarter

The equity has soared by 78% YoY but it is down by 7% from the previous quarter

The quick ratio has grown by 46% YoY but it has contracted by 20% from the previous quarter

Legend Biotech's debt has increased by 6% YoY

What are the main financial stats of LEGN

Market
Valuations
Earnings

Shares outstanding

181.91M

Market cap

$10.72B

Enterprise value

$9.9B

Price to earnings (P/E)

N/A

Price to book (P/B)

9.21

Price to sales (P/S)

31.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

28.89

Revenue

$342.8M

EBIT

-$445.78M

EBITDA

N/A

Free cash flow

-$323.2M

Per share
Balance sheet
Liquidity

EPS

-$2.58

Free cash flow per share

-$1.78

Book value per share

$6.4

Revenue per share

$1.88

TBVPS

$9.74

Total assets

$1.78B

Total liabilities

$611.05M

Debt

$334.69M

Equity

$1.16B

Working capital

$1.16B

Debt to equity

0.29

Current ratio

5.66

Quick ratio

5.23

Net debt/EBITDA

N/A

Margins
Efficiency
Dividend

EBITDA margin

N/A

Gross margin

52.4%

Net margin

-135.9%

Operating margin

-93.9%

Return on assets

-25.2%

Return on equity

-36.1%

Return on invested capital

-63.4%

Return on capital employed

-29.2%

Return on sales

-130%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Legend Biotech stock price performed over time

Intraday

0.32%

1 week

9.15%

1 month

38.3%

1 year

-21.07%

YTD

-2.06%

QTD

33.05%

How have Legend Biotech's revenue and profit performed over time

Revenue

$342.8M

Gross profit

$179.46M

Operating income

-$321.74M

Net income

-$465.95M

Gross margin

52.4%

Net margin

-135.9%

The operating margin has soared by 81% YoY and by 30% QoQ

Legend Biotech's net margin has surged by 73% YoY and by 25% QoQ

LEGN's operating income is up by 35% year-on-year and by 16% since the previous quarter

The gross profit has grown by 27% from the previous quarter

What is Legend Biotech's growth rate over time

What is Legend Biotech stock price valuation

P/E

N/A

P/B

9.21

P/S

31.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

28.89

The EPS has increased by 21% year-on-year and by 12% since the previous quarter

The equity has soared by 78% YoY but it is down by 7% from the previous quarter

The stock's price to book (P/B) is 6% more than its last 4 quarters average of 8.7

The P/S is 52% less than the 5-year quarterly average of 65.8 and 34% less than the last 4 quarters average of 47.1

The revenue is up by 20% since the previous quarter

How efficient is Legend Biotech business performance

The return on sales has surged by 74% year-on-year and by 26% since the previous quarter

The company's return on equity has surged by 63% YoY and by 19% QoQ

LEGN's return on assets is up by 46% year-on-year and by 17% since the previous quarter

LEGN's return on invested capital is up by 44% year-on-year and by 13% since the previous quarter

What is LEGN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for LEGN.

How did Legend Biotech financials performed over time

Legend Biotech's total assets is 191% more than its total liabilities

Legend Biotech's current ratio has increased by 47% YoY but it has decreased by 18% QoQ

Legend Biotech's total assets has increased by 47% YoY but it has decreased by 4% from the previous quarter

Legend Biotech's debt is 71% lower than its equity

The equity has soared by 78% YoY but it is down by 7% from the previous quarter

The debt to equity has contracted by 40% YoY but it has grown by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.